Proanthocyanidins from Ginkgo extract EGb 761® improve bioenergetics and stimulate neurite outgrowth in vitro
- PMID: 40575774
- PMCID: PMC12198615
- DOI: 10.3389/fphar.2025.1495997
Proanthocyanidins from Ginkgo extract EGb 761® improve bioenergetics and stimulate neurite outgrowth in vitro
Abstract
EGb 761® is a proprietary extract from Ginkgo biloba leaves approved as an herbal medication for the treatment of dementia and its related disorders. Preclinical studies highlight antioxidant, ROS scavenging, mitochondria-stabilizing, and neuroplastic properties as some of the reported pharmacological activities. Efficacy is traditionally ascribed to terpene lactones and flavone glycosides. However, these quantified known active compounds in EGb 761® only cover approximately 30% of the mass balance, and there is the possibility that additional compounds from the residual 70% may enhance the activity of the quantified extract EGb 761®. Proanthocyanidins (PACs) are a quantitatively relevant component in EGb 761®, and some pharmacological activity has been reported for PACs from Ginkgo and other herbal sources. In this study, we focused on the effects of EGb 761® and its isolated PACs on mitochondrial bioenergetics and neuroplasticity in the human neuroblastoma cell line SH-SY5Y. We successfully demonstrated positive effects of EGb 761® and its isolated PACs on several mitochondrial characteristics and neurite outgrowth. As PACs exhibited similar effects compared to the respective extract concentration, they can be considered a pharmacologically relevant component of EGb 761®.
Keywords: EGb 761®; bioenergetics; mitochondria; neurite outgrowth; proanthocyanidins.
Copyright © 2025 Lejri, Vukalović, Grimm and Eckert.
Conflict of interest statement
AE has received honoraria for educational lectures and consulting fees from Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures




Similar articles
-
Ginkgo biloba for cognitive impairment and dementia.Cochrane Database Syst Rev. 2002;(4):CD003120. doi: 10.1002/14651858.CD003120. Cochrane Database Syst Rev. 2002. Update in: Cochrane Database Syst Rev. 2007 Apr 18;(2):CD003120. doi: 10.1002/14651858.CD003120.pub2. PMID: 12519586 Updated.
-
Ginkgo biloba for cognitive impairment and dementia.Cochrane Database Syst Rev. 2007 Apr 18;(2):CD003120. doi: 10.1002/14651858.CD003120.pub2. Cochrane Database Syst Rev. 2007. Update in: Cochrane Database Syst Rev. 2009 Jan 21;(1):CD003120. doi: 10.1002/14651858.CD003120.pub3. PMID: 17443523 Updated.
-
Ginkgo biloba for cognitive impairment and dementia.Cochrane Database Syst Rev. 2009 Jan 21;(1):CD003120. doi: 10.1002/14651858.CD003120.pub3. Cochrane Database Syst Rev. 2009. PMID: 19160216
-
Antioxidant treatments for schizophrenia.Cochrane Database Syst Rev. 2016 Feb 5;2(2):CD008919. doi: 10.1002/14651858.CD008919.pub2. Cochrane Database Syst Rev. 2016. PMID: 26848926 Free PMC article.
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068
References
-
- Abdel-Kader R. M. (2009). Ginkgo biloba extract (EGb 761) in improving age-related and beta-amyloid induced neuronal dysfunctions. Johann Wolfgang Goethe-Universität. Available online at: https://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/7230 .
-
- Anaya-Fernández R., Anaya-Prado R., Anaya-Fernandez M. M., Guerrero-Palomera M. A., Garcia-Ramirez I. F., Gonzalez-Martinez D., et al. (2024). Oxidative stress in cerebral ischemia/reperfusion injury. OBM Neurobiol. 08 (03), 1–15. 10.21926/obm.neurobiol.2403239 - DOI
LinkOut - more resources
Full Text Sources
Research Materials